Novaquest Capital Management
NovaQuest Capital Management is a life-science investment firm focused on late-stage biopharmaceutical and animal health opportunities. The firm provides tailored, structured and non-dilutive capital solutions (branded PRODUCT FINANCE™) to advance pivotal clinical trials, launch products, monetize royalties and support commercialization. NovaQuest emphasizes a One Health perspective and integrates ESG considerations into its investment decision-making.
Industries
Nr. of Employees
small (1-50)
Novaquest Capital Management
4208 Six Forks Road, Suite 920, Raleigh, NC 27609
Portfolio
$30 million product financing agreement to develop veterinary pharmaceuticals in partnership with Argenta.
#Animal Health
Launch included acquisition of Enzyvant’s investigational therapy for Farber disease and $35 million product financing with NovaQuest.
#Biopharma (rare disease)
Announced $70 million non-dilutive product finance transaction to support continued development and extend cash runway.
#Biopharma
Secured $35M Series C financing led by Mountain Group Partners and NovaQuest to commercialize a vaccine delivery system for poultry.
#Animal Health
Announced a revenue interest financing agreement for up to $260 million in non-dilutive capital.
#Biopharma
$30 million product financing agreement to develop veterinary pharmaceuticals in partnership with Argenta.
#Animal Health
Launch included acquisition of Enzyvant’s investigational therapy for Farber disease and $35 million product financing with NovaQuest.
#Biopharma (rare disease)
Announced $70 million non-dilutive product finance transaction to support continued development and extend cash runway.
#Biopharma
Secured $35M Series C financing led by Mountain Group Partners and NovaQuest to commercialize a vaccine delivery system for poultry.
#Animal Health
Announced a revenue interest financing agreement for up to $260 million in non-dilutive capital.
#Biopharma